The immunomodulatory drug Leflunomide inhibits cell cycle progression of B-CLL cells.
Ringshausen
I
I
Oelsner
M
M
Bogner
C
C
Peschel
C
C
Decker
T
T
D017209:Apoptosis / Q000187:drug effects; D001402:B-Lymphocytes / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D003437:Crotonates / Q000494:pharmacology; D019925:Cyclin A / Q000378:metabolism; D056743:Cyclin D3; D051357:Cyclin-Dependent Kinase 2 / Q000037:antagonists & inhibitors; D016213:Cyclins / Q000378:metabolism; D004261:DNA Replication / Q000187:drug effects; D000090722:Dihydroorotate Dehydrogenase; D004354:Drug Screening Assays, Antitumor; D016193:G1 Phase / Q000187:drug effects*; D006801:Humans; D006885:Hydroxybutyrates; D007155:Immunologic Factors / Q000494:pharmacology*; D007555:Isoxazoles / Q000494:pharmacology*; D000077339:Leflunomide; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000473:pathology*; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D009570:Nitriles; D044925:Oxidoreductases Acting on CH-CH Group Donors / Q000037:antagonists & inhibitors; D010766:Phosphorylation / Q000187:drug effects; D011355:Prodrugs / Q000494:pharmacology; D011499:Protein Processing, Post-Translational / Q000187:drug effects; D011971:Receptors, Immunologic / Q000037:antagonists & inhibitors; D011982:Receptors, Prostaglandin / Q000037:antagonists & inhibitors; D016160:Retinoblastoma Protein / Q000378:metabolism; D014052:Toluidines / Q000494:pharmacology; D014407:Tumor Cells, Cultured / Q000187:drug effects; D051746:ZAP-70 Protein-Tyrosine Kinase / Q000032:analysis